Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Industry
Pharmaceutical Preparations
Location
26 Landsdowne Street, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.89 K % +40.7%
Debt-to-equity 9.17 % -29.1%
Return On Equity -40.6 % +18.1%
Return On Assets -37.2 % +15.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.2 M shares +0.64%
Common Stock, Shares, Outstanding 62.1 M shares +0.62%
Common Stock, Value, Issued 62 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62 K shares +3.79%
Weighted Average Number of Shares Outstanding, Diluted 62 K shares +3.79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 74.9 M USD -1.07%
General and Administrative Expense 40.2 M USD -5.29%
Operating Income (Loss) -113 M USD +1.7%
Net Income (Loss) Attributable to Parent -99.4 M USD +8.55%
Earnings Per Share, Basic -1.61 USD/shares +27.1%
Earnings Per Share, Diluted -1.61 USD/shares +27.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.9 M USD +15%
Other Assets, Current 47 K USD -81.8%
Assets, Current 218 M USD -28%
Property, Plant and Equipment, Net 4.77 M USD -27.4%
Operating Lease, Right-of-Use Asset 6.68 M USD -22.3%
Other Assets, Noncurrent 1.99 M USD -2.12%
Assets 233 M USD -27.6%
Accounts Payable, Current 3.86 M USD +2.09%
Employee-related Liabilities, Current 1.62 M USD -31.8%
Liabilities, Current 10.7 M USD -25.8%
Operating Lease, Liability, Noncurrent 8.11 M USD -20%
Other Liabilities, Noncurrent 197 K USD -38.4%
Liabilities 19 M USD -23.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -434 K USD +33.3%
Retained Earnings (Accumulated Deficit) -537 M USD -22.7%
Stockholders' Equity Attributable to Parent 214 M USD -27.9%
Liabilities and Equity 233 M USD -27.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.3 M USD -4.84%
Net Cash Provided by (Used in) Financing Activities 1.65 M USD -98.6%
Net Cash Provided by (Used in) Investing Activities 38.1 M USD
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 62.1 M shares +0.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5 M USD
Deferred Tax Assets, Valuation Allowance 130 M USD -21.3%
Deferred Tax Assets, Gross 133 M USD -20.5%
Depreciation 2.09 M USD -14.7%
Payments to Acquire Property, Plant, and Equipment 28 K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.2 M USD +8.38%
Property, Plant and Equipment, Gross 17.9 M USD +0.83%
Operating Lease, Liability, Current 2.03 M USD -23.7%
Deferred Tax Assets, Operating Loss Carryforwards 75 M USD -12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.19 M USD +29.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%